Roivant Sciences Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 863

Employees
  • Stock Symbol
  • ROIV

Stock Symbol
  • Investments
  • 28

  • Share Price
  • $8.55

  • (As of Friday Closing)

Roivant Sciences General Information

Description

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Contact Information

Website
www.roivant.com
Formerly Known As
Valor Biotechnology, Montes Archimedes Acquisition
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
  • 151 West 42nd Street
  • 15th Floor
  • New York, NY 10036
  • United States

Roivant Sciences Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Roivant Sciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.55 $8.37 $2.52 - $10.00 $6.07B 725M 2.23M -$1.69

Roivant Sciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021
EV 1,208,948 1,885,961
Revenue 50,416 55,286 23,795
EBITDA (1,261,064) (917,075) (897,156)
Net Income (1,177,997) (845,262) (809,234)
Total Assets 2,215,534 2,585,129 2,589,692
Total Debt 477,299 283,891 244,977
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Roivant Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Roivant Sciences‘s full profile, request access.

Request a free trial

Roivant Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Biotechnology
New York, NY
863 As of 2022
00.000
000000000 00.000

00000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000 000000000
San Diego, CA
000 As of 0000
00000
000000000 00000

00000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Roivant Sciences Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Heron Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 00000
00000 000000000000 Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
00000 Corporation Basel, Switzerland 000000 00.000 00000000000 00.000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 0000 000000000 0000
0000000-00000 0000 Corporation New York, NY 00000 00000 00000000000 00000
You’re viewing 5 of 14 competitors. Get the full list »

Roivant Sciences Executive Team (26)

Name Title Board Seat Contact Info
Matthew Gline Chief Executive Officer & Board Member
Richard Pulik Chief Financial Officer, Finance
Eric Venker MD Chief Operating Officer, Operations
Joyce Hong Principal, Roivant Health
Rakhi Kumar Chief Accounting Officer, Accounting
You’re viewing 5 of 26 executive team members. Get the full list »

Roivant Sciences Board Members (27)

Name Representing Role Since
000000 0000 Self Board Member 000 0000
00000 00000 00 Self Vant Chairman 000 0000
0000000 000000 Self Board Member 000 0000
0000 0000 Dexcel Pharma Board Member 000 0000
00000 00000000 Self Board Member 000 0000
You’re viewing 5 of 27 board members. Get the full list »

Roivant Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Roivant Sciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Roivant Sciences‘s full profile, request access.

Request a free trial

Roivant Sciences Investments & Acquisitions (28)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 07-Dec-2022 00 0000000 0000 Laboratory Services (Healthcare) 0000 0000
000000 000000 30-Sep-2021 0000000000 Special Purpose Acquisition Company (SPAC)
0000000000 02-Aug-2021 0000 00000 Drug Discovery 0000000 0
00000000 28-Jul-2021 00 0000000 Medical Records Systems 0000000 0
Silicon Therapeutics 26-Feb-2021 Buyout/LBO 00000 Drug Discovery 0000000 0
You’re viewing 5 of 28 investments and acquisitions. Get the full list »

Roivant Sciences Subsidiaries (4)

Company Name Industry Location Founded
Immunovant Drug Discovery New York, NY 2018
00000 0000000000 Biotechnology Oxford, United Kingdom 0000
000000000 00000000 Biotechnology Long Beach, CA 0000
0000000000 0000000 Drug Discovery Philadelphia, PA
To view Roivant Sciences’s complete subsidiaries history, request access »

Roivant Sciences ESG

Risk Overview

Risk Rating

Updated December, 07, 2022

27.46 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.0

Percentile

To view Roivant Sciences’s complete esg history, request access »

Roivant Sciences Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 00000000 24-Apr-2019 0000000000 Completed
  • 5 buyers
00000000 00000000 12-Jul-2016 00000 0000000 Completed
  • 2 buyers
Sio Gene Therapies Early Stage VC Completed
  • 3 buyers
To view Roivant Sciences’s complete exits history, request access »